Pediatric Community-Acquired Pneumonia: Antibiotic Choice Guide

TL;DR

• High-dose amoxicillin (80–90 mg/kg/day) remains the first-line pediatric pneumonia antibiotic choice for outpatient typical community-acquired pneumonia (CAP) in fully immunized children.
• Add a macrolide (azithromycin) when atypical pathogens (Mycoplasma pneumoniae, Chlamydophila pneumoniae) are suspected — most common in school-age children ≥5 years.
• Inpatient empiric therapy centres on IV ampicillin or ceftriaxone; add azithromycin if atypical pneumonia children presentation is likely.
• Most uncomplicated outpatient CAP resolves with 5–7 days of oral antibiotics; evidence supports shorter courses in selected patients.
• Red flags requiring urgent reassessment: respiratory distress, oxygen saturation <92%, inability to tolerate oral fluids, toxic appearance, or failure to improve after 48–72 hours of appropriate therapy.

§01What Is Pediatric Community-Acquired Pneumonia?

Community-acquired pneumonia (CAP) in children is an acute infection of the lung parenchyma acquired outside the hospital setting, presenting with fever, cough, tachypnoea, and — in younger children — often nonspecific signs such as poor feeding or abdominal pain. Pediatric pneumonia antibiotic choice hinges on age-stratified microbiology, vaccination status, and clinical severity.

CAP remains a leading cause of childhood morbidity worldwide. In high-income countries, the annual incidence in children under 5 years is approximately 15–25 per 1,000 child-years, declining to roughly 5–10 per 1,000 in older children. Hospitalisation rates have fallen substantially since widespread adoption of pneumococcal conjugate vaccines (PCV13/PCV15/PCV20), but Streptococcus pneumoniae persists as the dominant bacterial pathogen across all paediatric age groups. A landmark US CDC Etiology of Pneumonia in the Community (EPIC) study found that among children hospitalised for CAP, respiratory viruses were detected far more frequently than bacteria — underscoring the importance of not treating every pneumonia with antibiotics and reserving antimicrobials for cases with a bacterial aetiology or moderate-to-severe presentations.

Key Pathogens by Age Group

§02Empiric Antibiotic Options: Typical vs Atypical Coverage

Selecting the right empiric regimen requires answering two clinical questions: (1) Is a bacterial aetiology likely? and (2) Is the likely pathogen typical or atypical?

Typical CAP — Outpatient

For presumed bacterial CAP in a fully immunized child managed as an outpatient, high-dose oral amoxicillin is recommended as first-line therapy by the IDSA/Paediatric Infectious Diseases Society (PIDS) guidelines, the British Thoracic Society (BTS), and NICE. The rationale for high-dose amoxicillin (80–90 mg/kg/day) is to achieve middle-ear and lung concentrations that exceed the MIC of intermediately penicillin-resistant S. pneumoniae serotypes — a concern that persists despite PCV-era serotype shifts.

Second-line options include amoxicillin–clavulanate (when H. influenzae beta-lactamase production is suspected), oral cefuroxime, or oral clindamycin (where local S. pneumoniae resistance patterns favour it).

Atypical CAP — Outpatient

Atypical pneumonia in children — particularly those ≥5 years presenting with gradual-onset cough, low-grade fever, headache, and bilateral infiltrates — warrants empiric macrolide therapy. Azithromycin is the preferred macrolide due to its once-daily dosing, short course, and tolerability. Alternatives include clarithromycin or, in older adolescents, doxycycline.

When to add a macrolide to amoxicillin: If the clinician suspects mixed infection or cannot reliably distinguish typical from atypical features, combination therapy (amoxicillin + azithromycin) is a reasonable approach, especially in school-age children with moderate symptoms.

Comparison of Outpatient Empiric Regimens

§03Weight-Based Dosing Guide

Accurate weight-based dosing is critical in paediatric prescribing. The table below summarises standard doses per current guidelines.

Practical note on amoxicillin formulations: The 400 mg/5 mL suspension enables twice-daily dosing, which improves adherence. For a 20 kg child at 90 mg/kg/day, the total daily dose is 1,800 mg — i.e., 900 mg (11.25 mL of the 400 mg/5 mL suspension) twice daily. Always confirm available formulations in your jurisdiction.

§04Inpatient Empiric Therapy

Hospitalisation is indicated for children with moderate-to-severe CAP, including those with respiratory distress, hypoxaemia (SpO₂ <92%), inability to tolerate oral antibiotics, toxic appearance, or complicated pneumonia (effusion, empyema, necrotising features).

First-line inpatient therapy for typical CAP:

• IV ampicillin (150–200 mg/kg/day divided every 6 hours) — preferred for fully immunized children in regions with low rates of high-level penicillin-resistant pneumococcus.
• IV ceftriaxone (50–75 mg/kg/day, once daily) — preferred when broader gram-negative coverage is desired or local pneumococcal resistance is high.

When to add azithromycin inpatient:

Add IV or oral azithromycin (10 mg/kg day 1, then 5 mg/kg days 2–5) if the clinical presentation suggests atypical pneumonia or if the child is ≥5 years with features compatible with Mycoplasma infection. The IDSA/PIDS guidelines recommend adding a macrolide when atypical pathogens are suspected, not routinely for all inpatients.

Complicated CAP (empyema, lung abscess, necrotising pneumonia): These patients require broader-spectrum regimens — typically IV ceftriaxone or cefotaxime plus clindamycin (or vancomycin if MRSA is suspected). Paediatric infectious disease consultation is strongly advised.

§05Side Effects, Monitoring, and Antibiotic Stewardship

Common Adverse Effects

• Amoxicillin / amoxicillin–clavulanate: Diarrhoea (more common with clavulanate), nausea, maculopapular rash (non-allergic amoxicillin rash occurs in ~5–10% of children and does not preclude future use). Rare: anaphylaxis, Clostridioides difficile infection.
• Azithromycin: Abdominal pain, diarrhoea, nausea. Rare but important: QT prolongation — avoid in children with known long QT syndrome or concurrent QT-prolonging medications.
• Clindamycin: Diarrhoea, C. difficile-associated colitis (monitor for bloody or persistent diarrhoea). Metallic taste.
• Ceftriaxone: Injection site pain (IM), biliary sludging with prolonged use. Contraindicated in neonates receiving calcium-containing IV infusions (risk of fatal ceftriaxone-calcium precipitates).

Monitoring Recommendations

• Clinical response: Expect defervescence and symptomatic improvement within 48–72 hours of appropriate antibiotic therapy. Failure to improve warrants reassessment — consider resistant organism, empyema, viral aetiology, or alternative diagnosis.
• Routine follow-up chest radiograph is not recommended for uncomplicated CAP that resolves clinically (IDSA/PIDS, BTS). Reserve repeat imaging for complicated disease, persistent symptoms, or round/mass-like lesions requiring follow-up.
• Blood cultures are not routinely required for outpatient CAP but should be obtained before antibiotics in any child requiring hospitalisation.

Stewardship Considerations

Overuse of broad-spectrum antibiotics drives resistance. Key principles:

• Do not prescribe antibiotics for confirmed viral pneumonia in well-appearing, fully immunized preschool-age children. Supportive care is appropriate.
• Use narrow-spectrum agents when possible — amoxicillin over amoxicillin–clavulanate, ampicillin over ceftriaxone, unless clinical features dictate otherwise.
• Shortest effective course: The SCOUT-CAP trial demonstrated that a 5-day course of amoxicillin was non-inferior to a 10-day course for outpatient paediatric CAP, supporting shorter treatment durations in uncomplicated cases with early clinical response.

§06Contraindications and Drug Interactions

§07Special Populations

Neonates and Young Infants (<3 Months)

Pneumonia in this age group carries significant morbidity and mortality risk. Pathogens include Group B Streptococcus, Escherichia coli, Listeria monocytogenes, S. aureus, and Chlamydia trachomatis. All febrile infants <3 months with suspected pneumonia should be hospitalised for IV antibiotics (typically ampicillin + gentamicin or ampicillin + cefotaxime) pending culture results. Afebrile pneumonitis with staccato cough in infants 1–3 months raises concern for C. trachomatis, treated with oral azithromycin (20 mg/kg/day for 3 days, or 10 mg/kg/day for 5 days per AAP recommendations).

Immunocompromised Children

Children with primary immunodeficiency, malignancy, solid organ or haematopoietic stem cell transplant, or HIV require broadened empiric coverage and early infectious disease consultation. Consider Pneumocystis jirovecii, fungal pathogens, and atypical mycobacteria in addition to standard bacterial and viral aetiologies.

Children with Chronic Lung Disease or Neuromuscular Disorders

These children are at increased risk of aspiration pneumonia and infection with gram-negative organisms. Empiric therapy should include gram-negative coverage (e.g., amoxicillin–clavulanate or a third-generation cephalosporin) and anaerobic coverage for suspected aspiration.

Incompletely Immunized Children

Children who have not received age-appropriate pneumococcal and Haemophilus influenzae type b (Hib) vaccination are at higher risk for invasive bacterial pneumonia. Maintain a lower threshold for hospitalisation, blood cultures, and broader-spectrum empiric antibiotics (ceftriaxone preferred over ampicillin).

§08Red Flags — When to Seek Urgent Medical Care

Parents and caregivers should seek immediate medical attention if a child with pneumonia develops any of the following:

• Respiratory distress: nasal flaring, chest wall retractions (intercostal, subcostal, suprasternal), grunting
• Oxygen saturation <92% on room air (or cyanosis in any setting)
• Apnoea or irregular breathing — particularly in infants
• Inability to feed or drink — dehydration risk
• Toxic or lethargic appearance — reduced responsiveness, inconsolable irritability
• High, persistent fever (>39°C / 102.2°F) unresponsive to antipyretics beyond 72 hours of antibiotics
• Worsening symptoms after 48–72 hours of appropriate oral antibiotic therapy
• Signs of complicated pneumonia: pleuritic chest pain, large pleural effusion, haemoptysis

Clinical pearl: Tachypnoea — respiratory rate above age-specific norms (≥60/min in infants <2 months, ≥50/min in infants 2–12 months, ≥40/min in children 1–5 years, ≥20/min in children >5 years) — is the single most sensitive clinical sign for pneumonia in young children, per WHO criteria.

§09Frequently Asked Questions

1. Can viral pneumonia in children be treated with antibiotics?

No. Pure viral pneumonia does not respond to antibiotics, and prescribing them unnecessarily contributes to antibiotic resistance. In well-appearing, fully immunized preschool-age children with clinical and radiographic findings consistent with viral lower respiratory tract infection, supportive care (fluids, antipyretics, supplemental oxygen if needed) is appropriate. Antibiotics should be initiated if a bacterial co-infection is suspected or the child worsens.

2. Why is high-dose amoxicillin recommended instead of standard-dose?

High-dose amoxicillin (80–90 mg/kg/day) achieves serum and tissue concentrations sufficient to exceed the MIC of intermediately penicillin-resistant S. pneumoniae. Standard-dose amoxicillin (40–50 mg/kg/day) may fail against these strains. Since pneumococcal resistance patterns vary regionally but intermediate resistance is widespread, high-dose amoxicillin is now considered standard of care for empiric CAP treatment in children.

3. How long should antibiotics be given for uncomplicated outpatient CAP?

Current evidence, including the SCOUT-CAP randomised trial, supports 5 days as an effective duration for uncomplicated outpatient paediatric CAP treated with amoxicillin, provided the child shows clear clinical improvement by days 3–4. Some guidelines still recommend 7–10 days; clinical judgement should guide the decision. Complicated pneumonia (empyema, abscess) requires longer courses, often 2–4 weeks.

4. When should azithromycin be used instead of amoxicillin?

Azithromycin is preferred when atypical pneumonia is the most likely diagnosis — typically in school-age children (≥5 years) presenting with subacute, dry cough, low-grade fever, headache, and bilateral interstitial infiltrates. It is not a substitute for amoxicillin in treating S. pneumoniae, as macrolide resistance among pneumococci exceeds 30–40% in many regions.

5. Is it safe to use doxycycline in children under 8?

Traditionally, tetracyclines were avoided in children <8 years due to dental staining. However, the AAP has noted that doxycycline — unlike older tetracyclines — binds calcium less avidly and short courses (≤21 days) are unlikely to cause clinically significant tooth discolouration. Doxycycline may be considered in children of any age when the benefit outweighs the risk and alternatives are unavailable, though this remains a shared clinical decision.

6. Should a chest X-ray be done for every child with suspected pneumonia?

Not necessarily. For children with mild-to-moderate illness managed as outpatients, clinical diagnosis without chest radiography is acceptable per IDSA/PIDS and BTS guidelines. Chest X-ray is recommended when the diagnosis is uncertain, the child requires hospitalisation, or complicated pneumonia is suspected. A follow-up chest X-ray is not needed for uncomplicated cases that resolve clinically.

7. What if my child doesn't improve after 48–72 hours of antibiotics?

Failure to improve warrants medical reassessment. The clinician should consider: inadequate antibiotic spectrum (e.g., atypical pathogen not covered), resistant organism, development of a complication (parapneumonic effusion, empyema), or an alternative diagnosis entirely (foreign body, tuberculosis, malignancy). Additional investigations may include repeat chest imaging, blood cultures, and inflammatory markers.

8. Can probiotics prevent antibiotic-associated diarrhoea during pneumonia treatment?

Some evidence supports the use of select probiotic strains (e.g., Lactobacillus rhamnosus GG, Saccharomyces boulardii) to reduce antibiotic-associated diarrhoea in children. However, probiotics should not be given to immunocompromised children or those with central venous catheters due to the risk of probiotic-associated bloodstream infections. Discuss with your child's healthcare provider before initiating probiotics.

§10References

1. Bradley JS, Byington CL, Shah SS, et al. The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis. 2011;53(7):e25–e76. PMID: 21880587

2. Jain S, Williams DJ, Arnold SR, et al. Community-acquired pneumonia requiring hospitalization among U.S. children. N Engl J Med. 2015;372(9):835–845. PMID: 25714161

3. Harris M, Clark J, Coote N, et al. British Thoracic Society guidelines for the management of community acquired pneumonia in children: update 2011. Thorax. 2011;66(Suppl 2):ii1–ii23. PMID: 21903691

4. NICE. Pneumonia (community-acquired): antimicrobial prescribing. NICE guideline NG138. 2019. nice.org.uk/guidance/ng138

5. Williams DJ, Creech CB, Walter EB, et al. Short- vs standard-course outpatient antibiotic therapy for community-acquired pneumonia in children: the SCOUT-CAP randomized clinical trial. JAMA Pediatr. 2022;176(3):253–261. PMID: 35040926

6. Nascimento-Carvalho CM. Community-acquired pneumonia among children: the latest evidence for an updated management. J Pediatr (Rio J). 2020;96(Suppl 1):29–38. PMID: 31629677

7. FDA. Prescribing information: Amoxicillin capsules and oral suspension. DailyMed: Amoxicillin

8. WHO. Revised WHO classification and treatment of pneumonia in children at health facilities: evidence summaries. 2014. who.int/publications/i/item/9789241507813

9. Le Saux N, Robinson JL; Canadian Paediatric Society, Infectious Diseases and Immunization Committee. Uncomplicated pneumonia in healthy Canadian children and youth: practice points for management. Paediatr Child Health. 2015;20(8):441–450. PMID: 26744560

10. Biondi E, McCulloh R, Alverson B, et al. Treatment of mycoplasma pneumonia: a systematic review. Pediatrics. 2014;133(6):1081–1090. PMID: 24819576

§11About the Author

Dr. Stanislav Ozarchuk, PharmD, is a clinical pharmacist with 15 years of experience spanning hospital, ambulatory, and academic pharmacy settings. He holds a Doctor of Pharmacy degree and has contributed to antimicrobial stewardship programmes, formulary management, and patient education initiatives throughout his career. Dr. Ozarchuk writes for PillsCard.com with a focus on translating complex pharmacotherapy evidence into practical, guideline-grounded guidance for patients and healthcare professionals worldwide.

§12Medical Disclaimer

The information provided in this article is intended for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Antibiotic selection and dosing for paediatric pneumonia must be individualised based on the child's age, weight, allergy history, local resistance patterns, vaccination status, and clinical severity. Always consult a qualified healthcare professional before starting, stopping, or changing any medication. If your child is experiencing difficulty breathing, persistent high fever, or any red-flag symptoms described above, seek emergency medical care immediately. PillsCard.com and its contributors assume no liability for actions taken based on this content.